Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05604274
Other study ID # BAJAJ033
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 28, 2022
Est. completion date October 28, 2023

Study information

Verified date October 2022
Source Hunter Holmes Mcguire Veteran Affairs Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In patients with cirrhosis and healthy controls to determine the utility of an App to classify BSS compared to assessment made by the patients themselves using the BSS and correlate these with other stool characteristics and gut microbiota.


Description:

In patients with cirrhosis and healthy controls to determine the utility of an App to classify BSS compared to assessment made by the patients themselves using the BSS and correlate these with other stool characteristics and gut microbiota. Patients with cirrhosis are often treated with lactulose, that needs monitoring of bowel movement numbers and is overall not acceptable to a majority of patients. The estimation of this number is not completely accurate and varies day by day. In addition, recent work has shown that consistency of the stools with the Bristol Stool Scale (BSS) may be another important metric to determine who will respond well to lactulose versus not. In addition to the issue of remembering exact details of bowel movement frequency, it is often hard for patients, especially with HE, to remember details of their daily function. Additionally, insight into the impact of the disease. Traditionally, patients assess stool form and consistency using the Bristol stool score and chart, which classifies stool into one of seven types. A challenge with this is that the assessment is subjective and may vary from patient to patient. This is seen in patients without cognitive dysfunction such as those with irritable bowel syndrome (IBS). Therefore, it is likely that patients with cirrhosis, who often have cognitive dysfunction, could be worse in estimating stool consistency. In addition, microbiome structure and function, which is often dependent on stool consistency may be measured differently based on personal vs app-generated BSS values. Thus, method to better estimate stool characteristics, which could better inform patient management through telemedicine is needed. Aim: Monitor patients using a mobile health application designed for monitoring and assessing patients with digestive diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 28, 2023
Est. primary completion date October 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - For cirrhosis subjects must meet all of the following inclusion criteria to be eligible: 1. Male and female subjects aged = 18 years. 2. Cirrhosis 3. Able and willing to voluntarily complete the informed consent process 4. Familiar with smartphone technology 5. Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool For controls : 1. Male and female subjects aged = 18 years. 2. Absence of chronic diseases requiring prescription medications 3. Able and willing to voluntarily complete the informed consent process 4. Familiar with smartphone technology 5. Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool for microbiome analysis Exclusion Criteria: Subjects with cirrhosis meeting any of the following criteria are not eligible for study enrollment: 1. Unclear diagnosis of cirrhosis 2. History of liver transplant 3. For those on lactulose, they need to be on it for at least 2 weeks 4. Unfamiliar with smartphones 5. Apart from chronic liver disease, any acute or chronic medical, surgical, psychiatric, or social condition including history of cerebrovascular disease (stroke, transient ischemic attack) or dementia, that may increase the subject risk associated with study participation, compromise adherence to study procedures and requirements, confound interpretation of the results, and, in the judgment of the investigator, make the subject inappropriate for enrollment. For healthy controls 1. Any chronic disease requiring prescription medications 2. Unfamiliar with smartphones

Study Design


Related Conditions & MeSH terms


Intervention

Other:
App to monitor stool consistency and symptoms
App to monitor stool consistency and symptoms

Locations

Country Name City State
United States Hunter Holmes McGuire VA Medical Center Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
Hunter Holmes Mcguire Veteran Affairs Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary App use comfort measured by survey A survey designed to assess acceptability of this App at baseline and at 2 weeks; higher score=good 2 weeks
Secondary Quality of life using Sickness Impact Profile we will test association of the stool characteristics with quality of life; higher=good 2 weeks
Secondary Cognitive testing using PHES we will test association of the stool characteristics with PHES values; higher=good 2 weeks
Secondary Alpha diversity using Shannon index of microbiome we will test association of the stool characteristics with microbial characteristics 2 weeks
Secondary Bristol stool scale by subjects we will test association of the stool characteristics gauged through the App versus the Bristol stool scale by subjects 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Completed NCT04604860 - Use of EL-FIT App to Promote Physical Activity N/A
Recruiting NCT05928624 - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Recruiting NCT05998330 - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease N/A
Completed NCT04581369 - Cirrhosis Medical Home N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT05538962 - Longitudinal Monitoring of Inflammation in Cirrhosis N/A
Completed NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting NCT03736265 - Carvedilol for Prevention of Esophageal Varices Progression N/A
Recruiting NCT04530760 - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting NCT05093218 - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease. N/A
Recruiting NCT03437876 - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis N/A
Recruiting NCT04867954 - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT04121520 - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Not yet recruiting NCT04591522 - Fecal Microbiota Transplantation in Cirrhosis N/A